While U.S. label expansion efforts continue, CV Therapeutics Inc. granted ex-U.S. marketing rights for angina drug Ranexa (ranolazine prolonged-release tablets) to Menarini Group, of Florence, Italy. (BioWorld Today)
As of the end of August, biotech companies had raised $8.1 billion this year, less than half of the $19.3 billion raised in the same period last year, according to data from BioWorld Financial Watch. (BioWorld Financial Watch)
In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today)
